Loading
Vestibular and Auditory Disorders · Journal article
The Journal of International Advanced Otology · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This case report describes an 11-year-old boy with bilateral high-frequency sensorineural hearing loss detected 9 years after completion of cisplatin-based chemotherapy for hepatoblastoma. While the clinical presentation and temporal relationship suggest possible cisplatin ototoxicity, the single-patient nature and lack of comparative data prevent quantification of risk or mechanism; the case underscores a need for long-term audiological surveillance in childhood cancer survivors but does not establish incidence or causal mechanisms.
Case report. One 11-year-old boy with prior cisplatin-based chemotherapy for hepatoblastoma; evaluated by pure-tone audiometry, DPOAE, ABR, neuroimaging, and genetic testing.. Intervention: Prior cisplatin-based chemotherapy for hepatoblastoma (historical exposure).
Bilateral sensorineural hearing loss identified 9 years after cisplatin-based chemotherapy completion Pure-tone audiometry showed bilateral elevation of high-frequency thresholds without air–bone gap DPOAE absent at high frequencies and ABR elevated thresholds at 4 kHz
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This case alerts clinicians and audiologists caring for childhood cancer survivors to the possibility of delayed or previously undetected cisplatin ototoxicity emerging years after treatment. Long-term hearing surveillance may identify late deficits that would otherwise be missed by shorter-term follow-up protocols.
A single case report with retrospective observation of delayed sensorineural hearing loss; raises the clinical question of long-term cisplatin ototoxicity but provides no comparative data or quantified incidence.
As stated by the source record.
Quoted from the source exactly as published.
This case alerts clinicians and audiologists caring for childhood cancer survivors to the possibility of delayed or previously undetected cisplatin ototoxicity emerging years after treatment. Long-term hearing surveillance may identify late deficits that would otherwise be missed by shorter-term follow-up protocols.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Cisplatin is a widely used chemotherapeutic agent in pediatric oncology; however, it is well known for its marked ototoxicity. While hearing impairment typically emerges during or soon after therapy, progressive or previously undetected auditory dysfunction may occasionally present years later. The reported case involves an 11-year-old boy who previously received cisplatin-based chemotherapy for hepatoblastoma and was first identified as having bilateral sensorineural hearing loss 9 years after completion of treatment. Pure-tone audiometry revealed bilateral elevation of high-frequency thresholds without an air–bone gap, and distortion product otoacoustic emissions (DPOAE) were absent at high frequencies. Auditory brainstem responses (ABRs) demonstrated elevated thresholds at 4 kHz, and neuroimaging showed no structural abnormalities of the cochlea or auditory nerve. Expanded genetic testing revealed no pathogenic variants associated with hereditary hearing loss. Although the exact etiology could not be definitively established, the audiologic pattern and treatment history suggested that cisplatin may have contributed to the hearing loss. This case highlights the need for long-term hearing surveillance in childhood cancer survivors, as progressive or previously undetected deficits may not become clinically apparent until many years after treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.